Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices
Purpose: A variety of fixed-dose combination products is used in the therapy of Parkinson Disease. However, to date a proper analytical method applicable for comparative screening of different antiparkinson products was not available. The objective of the present work was thus to develop and validat...
Saved in:
Main Authors: | Erik Wollmer (Author), Sandra Klein (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2017-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018) -
Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease: A Single Center Real-World Experience
by: Szabolcs Szatmári, et al.
Published: (2024) -
Xanthonychia Due to Staining From Carbidopa-Levodopa
by: Jonathan Kyle Hwang, et al.
Published: (2023) -
Levodopa-benserazide Interaction with Enteral Nutrition: A Case Report
by: Foroud Shahbazi, et al.
Published: (2018) -
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
by: Song L,Yuan W, et al.
Published: (2012)